Matthew Shurtleff, PhD
Matt's scientific interests revolve around translating our basic understanding of cellular machinery into new therapies. He is a Senior Scientist at Lycia Therapeutics, a company founded by Carolyn Bertozzi (Nobel Prize in Chemistry, 2022) to degrade pathological extracellular and membrane proteins. Trained as a cell biologist, Matt received his PhD in Microbiology from UC Berkeley with Randy Schekman (Nobel Prize in Physiology or Medicine, 2013) and completed postdoctoral training at UCSF with Jonathan Weissman. Away from the lab, Matt enjoys hiking and skiing and sustains an unhealthy emotional investment in college football.